By Ben Glickman
GSK has received approval from the Food and Drug Administration for its treatment for myelofibrosis.
The British pharmaceutical company said Friday that Ojjaara had been approved for the treatment of intermediate or high-risk myelofibrosis patients with anemia.
The company said myelofibrosis is a blood cancer affecting about 25,000 patients in the U.S.
GSK initially submitted Phase 3 trial data on the drug, which has generic name momelotinib, in August 2022.
The treatment is approved for use regardless of whether patients have received prior myelofibrosis therapy.
Momelotinib isn’t currently approved in any other market.
Write to Ben Glickman at [email protected]
Read the full article here
